Australia has issued a warning about a rare visual disturbance linked to some medications used for diabetes and obesity, according to reports from جريدة المدينة.
The alert, covered by multiple outlets including جريدة المدينة and alyaum, highlights that certain drugs prescribed for type 2 diabetes and weight management may cause a rare eye condition. The reports did not specify the exact medication names or the precise nature of the visual disorder, but they describe it as an uncommon side effect that could lead to vision loss if left untreated.
This warning follows similar international scrutiny of GLP-1 receptor agonists, a class of drugs that includes semaglutide and liraglutide. These medications have become widely used for blood sugar control in diabetes and for weight loss, but regulators in several countries have previously flagged potential eye-related risks. The Australian health authorities are now urging patients and doctors to be aware of the symptoms.
According to the reports, the condition is considered rare, but the consequences can be serious. Patients experiencing sudden changes in vision, such as blurred sight or blind spots, are advised to seek medical attention promptly. The warning underscores the importance of monitoring for side effects even with widely prescribed treatments.
Health officials in Australia are expected to continue reviewing data on these medications. Patients currently taking such drugs should consult their healthcare provider if they have concerns about vision changes.
